New Editor-in-Chief Announcement
Wolters Kluwer is honored to announce that Anthony J. Rothschild, MD, will become an Editor-in-Chief of the Journal of Clinical Psychopharmacology (JCP) on January 1, 2021. Dr. Rothschild is the Irving S. and Betty Brudnick Endowed Chair in Psychiatry and Vice-Chair for Research in the Department of Psychiatry at the University of Massachusetts Medical School and UMass Memorial Health Care. Dr. Rothschild is an elected Fellow of the American College of Neuropsychopharmacology and the International College of Neuropsychopharmacology, which are the principal national and international scientific organizations for the study and treatment of psychiatric illnesses with psychotropic medications.
Dr. Rothschild has a distinguished career as a psychopharmacologist and biological psychiatrist. His clinical research has advanced scientific knowledge on the pathophysiology of treatment resistant depressive disorders and major depression with psychotic features. His research has been consistently funded with federal grants and he is widely published in both clinical and biologically focused medical journals.
“It is a tremendous honor and responsibility to join the editorial leadership of the Journal of Clinical Psychopharmacology upon the retirement of Founding Editor, Dr. Richard Shader, and to join Dr. David Greenblatt as an Editor-in-Chief of JCP,” Rothschild said. “Dr. Shader has provided exceptional leadership of the Journal for nearly 40 years since its founding in 1981. I am grateful to follow in his footsteps. I will seek to build on the foundation laid by Dr. Shader and to publish cutting-edge research in psychopharmacology that will impact our field. I believe the strength of the Journal of Clinical Psychopharmacology is the combination of its clinical focus, which directly impacts patient care, along with scientific advances with clinical applications”.